ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Molecular genetic characterisation of norovirus GII.17 strains circulating in South Korea in 2024.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDIn South Korea, norovirus outbreaks have been predominantly attributed to the GII.4 genotype; however, since mid-2024, strains harbouring the GII.17 genotype are being detected more frequently, raising concerns about a potential shift in the dominant circulating strain and resulting public health implications.AIMWe aimed to analyse the nt sequences of the gene encoding the viral protein 1 (VP1), the major capsid protein, of the GII.17 norovirus strains detected in South Korea in 2024, compare them with the corresponding nt sequences of the GII.17 Kawasaki 2014 lineage strains and evaluate whether GII.17 has the potential to replace the long-dominant GII.4 genotype.METHODSWe obtained 11 complete VP1 sequences from stool specimens collected across six regions in South Korea (Busan, Daejeon, Gangwon-do, Gyeongsangbuk-do, Incheon, Jeollanam-do) in 2024 and compared them with the VP1 sequence of the reference strain (GII.17 Kawasaki 2014) to identify genetic changes.RESULTSKey amino acid substitutions (R299P, N378D and K388R) were identified in the P2 domain of the VP1, which is a major antigenic site. Notably, N378D corresponds to D374 in the GII.4 genotype, which is a position involved in histo-blood group antigen (HBGA) binding, and K388R, adjacent to other antigenic sites, may alter the surface charge of the capsid.CONCLUSIONThe data provide molecular evidence that the emerging GII.17 strain in South Korea may evade the host immune surveillance machinery and exhibit altered receptor binding, underscoring the public health threat posed by this strain and the need for enhanced genomic surveillance and effective vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.